CXCL12 (SDF-1alpha) suppresses ongoing experimental autoimmune encephalomyelitis by selecting antigen-specific regulatory T cells.

J Exp Med · 2008 · PMC2571938 · PMID 18852294

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

highly significantno p-value reported

On day 15, when the therapeutic effect of CXCL12-Ig was highly significant ( Fig. 4 A ), spleens were removed.

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.